ProMIS Neurosciences Overview

  • Year Founded
  • 2004

Year Founded

  • Status
  • Public

  • Employees
  • 7

Employees

  • Stock Symbol
  • PMN

Stock Symbol

  • Investments
  • 2

  • Share Price
  • $1.61
  • (As of Friday Closing)

ProMIS Neurosciences General Information

Description

ProMIS Neurosciences Inc is a clinical-stage biotechnology company focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer's disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA). Its proprietary target discovery engine is based on the use of two complementary techniques. The company applies its thermodynamic, computational discovery platform-ProMIS and Collective Coordinates to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins.

Contact Information

Formerly Known As
Amorfix Life Sciences
Ownership Status
Publicly Held
Financing Status
Corporation
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Pharmaceuticals
Stock Exchange
NAS
Corporate Office
  • 1920 Yonge Street
  • Suite 200
  • Toronto, Ontario M4S 3E2
  • Canada

ProMIS Neurosciences Timeline

2021202220232024
Financing RoundCaptured Employee CountEstimated Employee Growth

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

ProMIS Neurosciences Stock Performance

(As of Friday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$1.61 $1.65 $0.95 - $8.95 $30.6M 19M 10.1K -$0.74

ProMIS Neurosciences Financials Summary

In Thousands,
USD
TTM 31-Mar-2024 FY 2023 31-Dec-2023 FY 2022 31-Dec-2022 FY 2021 31-Dec-2021
EV 19,448 5,095 34,656 32,069
Revenue 0 0 0 0
EBITDA (11,590) (12,990) (17,769) (9,328)
Net Income (11,888) (13,212) (18,062) (9,790)
Total Assets 3,548 13,619 6,925 17,747
Total Debt 108 94 1,859 3,906
Public Fundamental Data provided by Morningstar, Inc. disclaimer

ProMIS Neurosciences Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore ProMIS Neurosciences‘s full profile, request access.

Request a free trial

ProMIS Neurosciences Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
ProMIS Neurosciences Inc is a clinical-stage biotechnology company focused on generating and developing antibody therape
Drug Discovery
Toronto, Canada
7 As of 2023
000.00
000000000 000.00

000000

n ullamco laboris nisi ut aliquip ex ea commodo consequat. Duis aute irure dolor
0000 000000000
New York, NY
00 As of 0000
00.00
000000 - 000 00.00

000000

m, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo conse
0000 000000000
Malvern, PA
0 As of 0000
00000
000000000 00000
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

ProMIS Neurosciences Competitors (42)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Anavex Life Sciences Corporation New York, NY 00 00.00 000000 - 000 00.00
Annovis Bio Formerly VC-backed Malvern, PA 0 00000 000000000 00000
ALSP Venture Capital-Backed San Diego, CA 00 00.000 0000000000 00.000
CuraSen Venture Capital-Backed San Carlos, CA 00 000.00 00000000000 000.00
Alzheon Venture Capital-Backed Framingham, MA 00 00000 00000000000 00000
You’re viewing 5 of 42 competitors. Get the full list »

ProMIS Neurosciences Patents

ProMIS Neurosciences Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
EP-4143322-A1 Single chain antibodies and intrabodies to misfolded tdp-43 and methods of use Pending 29-Apr-2020 000000000
CA-3176840-A1 Single chain antibodies and intrabodies to misfolded tdp-43 and methods of use Pending 29-Apr-2020 000000000
AU-2021265165-A1 Single chain antibodies and intrabodies to misfolded tdp-43 and methods of use Pending 29-Apr-2020 000000000
JP-2023523066-A Single-chain antibodies and intrabodies against misfolded tdp-43 and methods of use Pending 29-Apr-2020 000000000
US-20230174630-A1 Single chain antibodies and intrabodies to misfolded tdp-43 and methods of use Pending 29-Apr-2020 C07K16/18
To view ProMIS Neurosciences’s complete patent history, request access »

ProMIS Neurosciences Executive Team (12)

Name Title Board Seat Contact Info
Neil Warma Chief Executive Officer & Board Member
Daniel Geffken Chief Financial Officer, Finance
Gavin Malenfant Chief Operating Officer, Operations
Neil Cashman Chief Scientific Officer & Board Member
Johanne Kaplan Ph.D Chief Development Officer
You’re viewing 5 of 12 executive team members. Get the full list »

ProMIS Neurosciences Board Members (9)

Name Representing Role Since
Eugene Williams ProMIS Neurosciences Chairman & Board Member 000 0000
Madge Shafmaster ProMIS Neurosciences Board Member 000 0000
Neil Cashman ProMIS Neurosciences Chief Scientific Officer & Board Member 000 0000
Neil Warma ProMIS Neurosciences Chief Executive Officer & Board Member 000 0000
Patrick Kirwin ProMIS Neurosciences Board Member 000 0000
You’re viewing 5 of 9 board members. Get the full list »

ProMIS Neurosciences Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

ProMIS Neurosciences Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore ProMIS Neurosciences‘s full profile, request access.

Request a free trial

ProMIS Neurosciences Investments & Acquisitions (2)

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
Developer of Tests for Detection of Alzheimer's Disease (ProMIS Neurosciences / BC Neuroimmunology) 09-Jul-2020 00000 0000 Diagnostic Equipment 000000 00
Amorfix Life Sciences 08-Jul-2015 Merger/Acquisition Therapeutic Devices
To view ProMIS Neurosciences’s complete investments and acquisitions history, request access »

ProMIS Neurosciences FAQs

  • When was ProMIS Neurosciences founded?

    ProMIS Neurosciences was founded in 2004.

  • Who is the founder of ProMIS Neurosciences?

    Neil Cashman and Vigen Nazarian are the founders of ProMIS Neurosciences.

  • Who is the CEO of ProMIS Neurosciences?

    Neil Warma is the CEO of ProMIS Neurosciences.

  • Where is ProMIS Neurosciences headquartered?

    ProMIS Neurosciences is headquartered in Toronto, Canada.

  • What is the size of ProMIS Neurosciences?

    ProMIS Neurosciences has 7 total employees.

  • What industry is ProMIS Neurosciences in?

    ProMIS Neurosciences’s primary industry is Drug Discovery.

  • Is ProMIS Neurosciences a private or public company?

    ProMIS Neurosciences is a Public company.

  • What is ProMIS Neurosciences’s stock symbol?

    The ticker symbol for ProMIS Neurosciences is PMN.

  • What is the current stock price of ProMIS Neurosciences?

    As of 14-Jun-2024 the stock price of ProMIS Neurosciences is $1.61.

  • What is the current market cap of ProMIS Neurosciences?

    The current market capitalization of ProMIS Neurosciences is $30.6M.

  • Who are ProMIS Neurosciences’s competitors?

    Anavex Life Sciences, Annovis Bio, ALSP, CuraSen, and Alzheon are some of the 42 competitors of ProMIS Neurosciences.

  • What is ProMIS Neurosciences’s annual earnings per share (EPS)?

    ProMIS Neurosciences’s EPS for 12 months was -$0.74.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read blog »
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process »